Advisory Services Network’s Purple Biotech PPBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$36 Buy
+9
New +$49 ﹤0.01% 4778
2025
Q4
Sell
-10
Closed -$57 3620
2025
Q3
$57 Buy
+10
New +$179 ﹤0.01% 4458
2024
Q1
Sell
-10
Closed -$1.56K 3086
2023
Q4
$1.56K Buy
+10
New +$2.21K ﹤0.01% 3455
2023
Q2
Sell
-10
Closed -$3.57K 3068
2023
Q1
$3.57K Hold
10
﹤0.01% 3258
2022
Q4
$2.75K Buy
+10
New +$3.84K ﹤0.01% 3320
2021
Q3
Sell
-10
Closed -$9K 2749
2021
Q2
$9K Buy
+10
New +$9.18K ﹤0.01% 2865
2021
Q1
Sell
-10
Closed -$7K 2528
2020
Q4
$7K Hold
10
﹤0.01% 2602
2020
Q3
$9K Hold
10
﹤0.01% 2505
2020
Q2
$22K Buy
10
+5
+100% +$4.91K ﹤0.01% 1038
2020
Q1
$3K Hold
5
﹤0.01% 2662
2019
Q4
$8K Buy
5
+4
+400% +$5.84K ﹤0.01% 2455
2019
Q3
$1K Hold
1
﹤0.01% 2731
2019
Q2
$1K Hold
1
﹤0.01% 2729
2019
Q1
$2K Buy
+1
New +$2.41K ﹤0.01% 2346

Other funds holding PPBT

Advisory Services Network's PPBT Position: Q1 2026 in Review

Advisory Services Network opened a new position in Purple Biotech (PPBT) in Q1 2026: 9 shares worth $36. The stake represents ﹤0.01% of the portfolio and ranks #4778 among its holdings. This is a return to the name: Advisory Services Network previously reported a position in PPBT as recently as Q3 2025.

Advisory Services Network first reported a position in PPBT in Q1 2019 and has held it in 14 quarters since. The position peaked at $22K in Q2 2020. 15 funds tracked by Wall St. Rank hold PPBT as of Q1 2026.

  • Advisory Services Network held 9 shares of Purple Biotech worth $36 as of Q1 2026.
  • Purple Biotech was a new Advisory Services Network position in Q1 2026.
  • Purple Biotech made up ﹤0.01% of Advisory Services Network's portfolio in Q1 2026, its #4778 holding.
  • Advisory Services Network first reported a position in Purple Biotech in Q1 2019 and has held it in 14 quarters since.
  • Advisory Services Network's Purple Biotech position peaked at $22K in Q2 2020.
  • 15 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2026.

Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.